TD Cowen Maintains Outperform on Ginkgo Bioworks Holdings, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steven Mah maintains an Outperform rating on Ginkgo Bioworks Holdings (NYSE:DNA) but lowers the price target from $7 to $3.

March 01, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen maintains an Outperform rating on Ginkgo Bioworks Holdings but lowers the price target from $7 to $3.
While the maintenance of an Outperform rating by TD Cowen indicates continued confidence in Ginkgo Bioworks Holdings' potential, the significant reduction in the price target from $7 to $3 could signal concerns about near-term challenges or valuation adjustments. This mixed signal might lead to short-term market uncertainty for DNA's stock, balancing out potential positive and negative impacts.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100